MTOR and autosomal dominant polycystic kidney disease: As mTOR has previously been assessed as a therapeutic target in ADPKD, inhibition of this miRNA suggests an additional treatment option, especially as clinical trials of the mTOR inhibitor rapamycin and its analogues have demonstrated issues with tolerability and failed to show efficacy [50].